v3.10.0.1
Condensed Consolidated Interim Balance Sheets - USD ($)
Jun. 30, 2018
Mar. 31, 2018
Current    
Cash and cash equivalents $ 959,704 $ 507,311
Trade accounts receivable (net of allowance for doubtful accounts of $19,694; March 31, 2018 - $19,694) 370,180 212,730
Prepaid expenses and other receivables (Note 5) 485,438 433,655
Inventories (Note 6) 155,795 237,443
Due from related parties (Note 9(a) 18,547 18,897
Total Current Assets 1,989,664 1,410,036
Equipment (Note 7) 150,210 159,961
Technology and other Assets (Note 4) 4,635,666 4,706,719
Goodwill 22,308,275 22,308,275
Total Assets 29,083,815 28,584,991
Current    
Accounts Payable (Notes 9(b) and 13) 736,141 724,673
Accrued liabilities (Notes 8 and 9(b)) 1,127,364 1,529,505
Customer advances 800 800
Demand Loans (Note 8) 0 51,479
Convertible Loans (Note 8) 1,692,187 0
Conversion Feature on Convertible Loans (Note 8) 1,455,655 0
Deferred revenue 129,784 122,667
Shares to be issued, stock options and warrants (Notes 10,11 and 12) 0 5,692,853
Total Current Liabilities 5,141,931 8,121,977
Shareholders' Equity    
Preferred Stock, par value $0.001; Authorized - 10,000,000; Special Voting Preferred Stock, par value $0.001; Authorized, issued and outstanding - 1 (March 31, 2018 – 1) 0 0
Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 247,873,882 and 41,271,880 Exchangeable Shares (March 31, 2018 - 205,328,106 and 44,271,880 Exchangeable Shares) (Note 10) 289,145 249,599
Additional paid-in capital 60,147,628 55,947,606
Deficit (36,537,038) (35,776,340)
Accumulated other comprehensive income 42,149 42,149
Total Shareholders' Equity 23,941,884 20,463,014
Total Liabilities and Shareholders' Equity $ 29,083,815 $ 28,584,991

Source

v3.10.0.1
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Sales $ 501,333 $ 87,520
Cost of Sales 253,163 29,300
Gross Margin 248,170 58,220
Operating expenses    
Sales and marketing 542,659 445,525
Research and development 676,743 685,909
General and administrative 979,479 627,606
Share-based compensation expense (Note 11) 595,412 251,048
Amortization (Note 4) 71,053 92,949
Depreciation (Note 7) 17,595 24,552
Total operating expenses 2,882,941 2,127,589
Other (income) expense    
Foreign exchange (41,134) 98,561
Accretion expense (Note 8) 134,251 0
Fair value adjustment (Note 8) 44,087 0
Gain on mark to market reevaluation (2,048,697) 0
Other expense 37,420 72,588
Total other (income) expenses (1,874,073) 171,149
Net loss and comprehensive loss for the period $ (760,698) $ (2,240,518)
Loss per share – basic $ 0.00 $ (0.02)
Loss per share – diluted $ 0.00 $ (0.02)
Weighted average number of shares outstanding – basic 257,509,141 96,959,284
Weighted average number of shares outstanding – diluted 257,509,141 96,959,284

Source

v3.10.0.1
Condensed Consolidated Interim Statements of Cash Flows - USD ($)
3 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Operating activities    
Net loss for the period $ (760,698) $ (2,240,518)
Adjustment for items not affecting cash    
Depreciation 17,595 24,552
Amortization 71,053 92,949
Interest expense 36,702 72,766
Share based compensation expense 595,412 251,048
Accretion expense 134,251 0
Fair value adjustment 44,087 0
Gain on mark to market reevaluation (2,048,697) 0
Allowance for doubtful accounts (19,694) 0
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities (1,929,989) (1,799,203)
Changes in non-cash working capital items    
Accounts receivable (137,756) 248,977
Prepaid expenses and other receivables (51,783) 55,996
Due from related parties 350 (635)
Inventories 81,648 (27,297)
Accounts payable 11,468 104,648
Accrued liabilities (402,141) (5,428)
Customer advances 0 108,300
Deferred revenue 7,117 7,985
Net cash (used in) operating activities (2,421,086) (1,306,657)
Investing activities    
Acquisition of equipment (7,844) (15,600)
Net cash (used in) investing activities (7,844) (15,600)
Financing activities    
Proceeds from convertible loans 2,934,298 500,000
Proceeds on exercise of warrants 0 1,125,038
Repayment of Demand notes principal (50,000) 0
Repayment of Promissory notes interest (2,975) 0
Net cash provided by financing activities 2,881,323 1,625,038
Net increase in cash and cash equivalents for the period 452,393 302,781
Cash and cash equivalents, beginning of period 507,311 543,650
Cash and cash equivalents, end of period $ 959,704 $ 846,431

Source